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The chemokine receptor CXCR4 acts as a key cell surface receptor in HIV infections, multiple forms of
cancer, and various other pathologies, such as rheumatoid arthritis and asthma. Macrocyclic polyamines
and their metal complexes are known to exert anti-HIV activity, many acting as HIV entry inhibitors by
specifically binding to CXCR4. Three series of pyridopentaazacylopentadecanes, in which the pyridine
ring is fused to zero, one, or two saturated six-membered rings, were synthesized by manganese(II)-tem-
plated Schiff-base cyclization of triethylenetetramine with various dicarbonyl compounds. By evaluating
these macrocyclic polyamines and their complexes with Mn2+, Cu2+, Fe3+, and Zn2+, we have discovered
novel CXCR4-binding compounds. The MnCl2 complex of a new pentaazacyclopentadecane with one
fused carbocyclic ring (11) was found to have the greatest potency as an antagonist of the chemokine
receptor CXCR4 (IC50: 0.014 µM), as evidenced by inhibiting binding of CXCL12 to PBMCs (peripheral
blood mononuclear cells). Consequently, this compound inhibits replication of the CXCR4-using (X4)
HIV-1 strain NL4-3 in the TZM-bl cell line with an IC50 value of 0.52 µM and low cytotoxicity (CC50: >100
µM). In addition, 18 other compounds were evaluated for their interaction with CXCR4 via their ability to
interfere with ligand chemokine binding and HIV entry and infection. Of these, the metal complexes of
the two more hydrophobic series with one or two fused carbocyclic rings exhibited the greatest potency.
The Zn2+ complex 21 was among the most potent, showing that redox activity of the metal center is not
associated with CXCR4 antagonist activity.
Introduction
The chemokine receptor CXCR4 belongs to the G-protein
coupled receptor superfamily and acts as a key cell surface
receptor in human immunodeficiency virus (HIV) infections,
multiple forms of cancer, and various other pathologies, such
as rheumatoid arthritis and asthma. CXCR4 regulates leuko-
cyte trafficking in inflammation and has additional roles in
the development of the hematopoietic, cardiovascular, and
nervous systems during embryogenesis.1 CXCR4 also serves in
conjunction with CD4 as a coreceptor for entry of a number of
specific (CXCR4-using or T-tropic) strains of HIV-1 and several
low molecular weight CXCR4 antagonists have been shown to
suppress HIV-1 replication by profoundly inhibiting the viral
entry process.2,3 The drug combination therapy known as
highly active anti-retroviral therapy (HAART), which often con-
sists of reverse transcriptase inhibitors and a protease inhibi-
tor, has markedly decreased HIV-1 associated morbidity and
mortality.4 Yet, to anticipate emergence of drug-resistant
viruses, the discovery of novel anti-HIV-1 agents with new
mechanisms of action (e.g. entry inhibitors) is still needed to
ensure effective anti-HIV-1 treatment. In addition, CXCR4
antagonists are also of interest for treatment of cancer,5,6 rheu-
matoid arthritis, and WHIM (warts, hypogammaglobulinemia,
infections and myelokathexis) syndrome.7,8
Bicyclams, such as AMD3100 (Fig. 1a), are macrocyclic poly-
amines known to inhibit HIV infection by blocking CXCR4.9–11
AMD3100 is under investigation for counteracting opioid-
induced hyperalgesia produced by chronic treatment with
†Electronic supplementary information (ESI) available: Syntheses and character-
ization data for compounds 2, 4, 5, and 10–21. Numbered thermal ellipsoid
plots and X-ray crystallographic data for three compounds, 2, 4, and 17. 1H and
13C NMR spectra of compounds 6, 8, 12, 15, 18 and 21. CCDC 1062374–1062376.
For ESI and crystallographic data in CIF or other electronic format see DOI:
10.1039/c5ob01557j
‡These authors contributed equally.
aDepartment of Chemistry, University of Nevada, Reno, NV, USA.
E-mail: twb@unr.edu
bDepartment of Microbiology and Immunology, Rega Institute for Medical Research,
University of Leuven, Leuven, Belgium. E-mail: Dominique.Schols@rega.kuleuven.be
cDepartment of Experimental Medicine and Biochemical Sciences, University of Rome
Tor Vergata, Rome, Italy
This journal is © The Royal Society of Chemistry 2015 Org. Biomol. Chem., 2015, 13, 10517–10526 | 10517
Pu
bl
ish
ed
 o
n 
25
 A
ug
us
t 2
01
5.
 D
ow
nl
oa
de
d 
by
 K
U
 L
eu
ve
n 
U
ni
ve
rs
ity
 L
ib
ra
ry
 o
n 
22
/1
0/
20
15
 0
6:
04
:4
9.
 
View Article Online
View Journal  | View Issue
morphine12 and for treating pancreatic cancer. CXCR4 antag-
onists like the bicyclams and their metal complexes can act as
anti-tumor agents by preventing malignant cells from interact-
ing with the tumor microenvironment, making them sensitive
to chemotherapy.13 AMD3100 has also been approved in the
USA for stem cell mobilization.14 It is of interest to determine
whether other macrocyclic polyamines and their metal com-
plexes can be designed with improved antagonist activity for
CXCR4. Interestingly, the manganese-containing metallo-
enzyme superoxide dismutase (SOD) has been reported to
inhibit HIV replication,15 while an SOD mimic consisting of
the manganese complex of a pyridine-fused macrocyclic polya-
mine (M40401,16,17 a dimethyl analog of M40403,18,19 Fig. 1b)
was reported to inhibit apoptosis in HIV-infected cells by redu-
cing oxidative stress.20
M4040318,19 is one of a series of SOD mimetic manganese
complexes investigated by MetaPhore Pharmaceuticals as
potential therapeutic agents for inflammation and ischemia-
reperfusion injury.21,22 Complexes of three metals (Fe, Mn,
and Cu) are known to catalyze the conversion of superoxide
anion to oxygen and hydrogen peroxide, but manganese is the
least toxic in mammals.21,22 Moreover, pyridine-containing
macrocyclic polyamines were found to form very stable tran-
sition metal complexes, providing metabolic stability. Because
of its high SOD-mimetic potency and favorable drug-like pro-
perties, M40403 was selected for clinical trials as an analgesic
co-administered with an opioid for cancer pain and for preven-
tion of dose limiting toxicities in treatment of melanoma or
carcinoma with interleukin 2 (IL-2)23 and was shown to be
“safe and well-tolerated”.24 M40403 was also found to prevent
oral mucositis induced by radiation or chemotherapy in ham-
sters25 and was approved in 2008 as an orphan drug for this
use in cancer patients.24 The purpose of this current study,
based on the metal binding capacities of the bicyclams and
their antiviral potency, was to determine whether metal com-
plexes of macrocyclic polyamines similar to M40403 bind to
CXCR4 and inhibit HIV-1 entry by this mechanism.
The new molecular scaffold of interest in the current study
is illustrated in Fig. 1c. Here, the dashed lines indicate poten-
tial cyclohexane rings fused to the central pyridine ring. The
parent manganese complex lacking additional fused rings,
compound 1 (Fig. 1d), has been described previously.21,26–28
Compounds containing additional fused rings were designed
to explore the effect of increased hydrophobicity on chemokine
receptor interactions and to evaluate their potential CXCR4
binding and anti-HIV activity. Many cationic molecules
bearing hydrophobic groups bind to the chemokine binding
site of CXCR4 used for entry of HIV, and the chemokine
CXCL12 binds to CXCR4 via a combination of electrostatic,
hydrogen bonding and hydrophobic interactions.29 Fusion of
carbocyclic rings directly to the central pyridine ring in the
target compounds facilitated chemical synthesis. Additional
metal complexes in which the manganese atom is replaced by
copper, iron, or zinc were of interest to determine if any anti-
HIV activity is related to SOD mimetic activity, as zinc is not
redox active and thus is not able to act as an SOD mimic.
Results and discussion
Chemistry
The initial synthetic target was the parent manganese complex
1, lacking additional rings fused to the central pyridine ring
(Fig. 1d). Two methods have been reported for synthesis of
manganese complexes of pyridine-fused 15-membered macro-
cyclic pentamines: (1) Mn2+ templated condensation of 2,6-
pyridinedicarboxaldehyde with triethylenetetramine to form
the intermediate Schiff base macrocycle complex,30 followed
by reduction of the Schiff base moieties;27 or, (2) synthesis of
the metal-free macrocycle as described by Stetter31 (aka the
Richman–Atkins method32,33), followed by complexation of the
manganese salt.21,26,28 The metal template method appears to
work better for condensations of 2,6-diacetylpyridine,16,34–36
but it has been applied successfully to the corresponding di-
aldehyde by Dees et al. in their synthesis of 1,27 and by Malik
et al. in their synthesis of Schiff base MnI2 complex 2
(Scheme 1).37 Drahos et al. later reported failure with Dees’
method and used the Stetter approach.28
The results of our efforts to prepare the Schiff-base precur-
sor (3, Scheme 1) to macrocyclic manganese complex 1 are
shown in Scheme 1. We first attempted to condense pyridine-
2,6-dicarboxaldehyde38 with triethylenetetramine by heating
with manganese(II) chloride in methanol or ethanol, as
described by Drew et al.,30,35 but we were not able to crystallize
the desired product (3) from the crude mixture. Switching the
template salt to manganese(II) acetate and adding aqueous
Fig. 1 Structures of bicyclam AMD3100 (a), SOD mimic M40403 (b), and compounds of interest in the current study (c), including parent MnCl2
complex 1 (d).
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potassium iodide enabled the isolation of the corresponding
MnI2 complex 2 in good yield.
37 A further attempt to prepare
the MnCl2 complex in methanol at room temperature resulted
in the isolation of double Mn2+ complex 4 (Scheme 1), com-
posed of two pyridine-2,6-dicarboxaldehyde and three triethyl-
enetetramine moieties. The structures of 2 and 4 were
determined by X-ray crystallography (vide infra). Dees et al.
accomplished the two-step synthesis of 1 by condensation in
boiling water,27 without isolating intermediate Schiff-base
complex 3. By a variation of their method with methanol as a
co-solvent, we were able to isolate the desired MnCl2 complex
3 by column chromatography. Attempts were made to template
macrocyclizations with other metal cations (Cu2+, Fe3+ or
Zn2+), but Mn2+ was most effective, so complexes of these
metals were prepared later by demetallation of the Mn2+
complex and complexation of the free ligand.
Solid-state molecular structures of Mn2+ complexes 2 and 4
are shown in Fig. 2. Schiff-base macrocyclic MnI2 complex 2
Scheme 1 Manganese(II) templated condensation of pyridine-2,6-
dicarboxaldehyde with triethylenetetramine. Reagents and conditions:
(a) 2: (1) Mn(OAc)2, (CH2NHCH2CH2NH2)2, MeOH, reflux, 6 h; (2) KI, H2O,
rt. 3: MnCl2, (CH2NHCH2CH2NH2)2, MeOH, H2O, reflux, 3 h. (b) MnCl2,
(CH2NHCH2CH2NH2)2, MeOH, rt, 6 h.
Fig. 2 Thermal ellipsoid representations of the Mn(II) complexes 2 (a) and 4 (b). Color scheme: C grey, N blue, O red, Cl green, I pink. Only the cat-
ionic portion of each complex is shown with an iodide and water omitted for 2 and two chlorides and two waters omitted for 4. Hydrogen atoms
have also been omitted for clarity. Note: the structure of 2 represents the molecule shown in Scheme 1 after replacement of one iodide ligand by
water.
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displays the expected seven-coordinate pentagonal bipyramidal
geometry, although one of the axial iodide ligands is replaced
by a water molecule and there is an additional non-
coordinated water of crystallization. Halide ligands in Mn2+
complexes of pentadentate nitrogen macrocycles are known to
dissociate from the metal center in aqueous solution.27 In
Mn2+ complex 4 the carbonyl groups form aminals, rather
than imines, and the metal centers are only six-coordinate,
perhaps due to steric congestion. Formation of such oligo-
meric aminals and other side products may limit yields and
hinder crystallization of desired Mn2+ complexes of Schiff-base
macrocycles.
Syntheses of parent macrocyclic metal complexes lacking
additional rings fused to the central pyridine ring are shown
in Scheme 2. Since the yield of Schiff base macrocycle complex
3 was low and purification required column chromatography,
crude 3 was reduced with sodium borohydride, as described
by Dees et al.,27 to give the parent MnCl2 complex 1. The yield
of pure 1 for this two-step process was higher than for one-step
synthesis of intermediate 3, perhaps due to decomposition
and/or solvent exchange of chloride during chromatography of
3. The same sequence of reactions applied to 4-methyl-2,6-
pyridinediacarboxaldehyde38 gave methyl substituted analog 5,
which was desired to test the effect of increased hydrophobi-
city. Metal-free parent ligand 6 was prepared in high yield by
displacing Mn(II) from 1 with aq. HCl, followed by treatment
with NaOH and filtration to remove precipitated metal salts.
Reaction of 6 with FeCl3, ZnCl2, or CuCl2 in ethanol gave
corresponding complexes 7, 8, and 9 as precipitates in good to
excellent yields.
Syntheses of metal complexes of macrocycles with one or
two saturated six-membered rings fused to the pyridine ring
(tetrahydroquinolines or octahydroacridines) are shown in
Scheme 3. MnCl2 templated condensation of 6,7-dihydro-8-
(5H)-quinolinone-2-carboxaldehyde39 or 2,3,7,8-tetrahydroacri-
dine-4,5-(1H,6H)-dione40 with triethylenetetramine carried out
in boiling water or aqueous ethanol afforded Schiff base
macrocycle complexes 10 or 16 in modest yields after puri-
fication by column chromatography. As observed in the parent
series, reaction of the crude intermediate with sodium boro-
hydride gave the reduced products 11 or 17 in higher overall
yield for two steps. Metal-free ligands 12 and 18 were obtained
in good yields by the same protonation/deprotonation
sequence used for parent ligand 6, then the complexes of
CuCl2 (13 and 19), FeCl3 (14 and 20), and ZnCl2 (15 and 21)
were prepared in excellent yields. All new compounds were
characterized by mass spectrometry, infrared spectroscopy,
and combustion microanalysis, as well as 1H/13C NMR spectro-
scopy, except for complexes of the paramagnetic metal ions,
Mn(II) and Cu(II). The 1H and 13C NMR spectra of zinc com-
plexes 15 and 21 showed two species in solution, possibly a
mixture in which one of the axial chloride ligands is replaced
by water, as seen in the solid state structure of MnI2 complex 2
(Fig. 2a).
Octahydroacridine-containing ligand 18 has two symmetry
related stereocenters and therefore can exist in meso or D,L dia-
stereomers. Single crystals of the of Mn(II) complex 17 were
obtained and the crystal structure was determined by X-ray
crystallography, showing only the D,L diastereomer. The solid-
state structure of this complex shown in Fig. 3 displays penta-
gonal bipyramidal geometry about the metal center with two
axial chloride ligands and proves the relative configuration of
the ligand. Bulk samples of 17 appear to consist of only one
isomer by tlc and hplc analysis. Free ligand 18 also apparently
consists of a single isomer by NMR and chromatographic
analysis, so the D,L ligand structure is assigned to all
products 17–21.
Biological evaluation
To determine the ability of the SH compounds to inhibit the
CXCL12/CXCR4 axis, a direct CXCL12 binding inhibition assay
was performed with PBMCs (peripheral blood mononuclear
cells) to study the competitive binding of the compounds on
the CXCR4 receptor. The results are presented in Table 1.
Manganese complex 11 with one fused six-membered ring was
the most potent inhibitor overall, with an IC50 value of 14 nM.
The corresponding metal-free ligand (12) and its Cu, Fe and
Zn complexes (13–15) were also active, but less potent (IC50:
0.13–1.1 μM). All of the corresponding compounds with no
fused ring (1, 6 and 7–9) were less potent. While Mn complex
17 with two fused rings was less potent than 11, the Cu, Fe
Scheme 2 Syntheses of parent macrocyclic metal complexes and free ligand (6). Reagents and conditions: (a) (1) MnCl2, (CH2NHCH2CH2NH2)2,
H2O, reflux, 3 h; (2) NaBH4, EtOH, 50 °C, 5 h; (3) LiCl, MeOH; (4) NaCl, H2O. (b) (1) 1, HCl, H2O, rt, 30 min; (2) NaOH, H2O. (c) M, EtOH.
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and Zn complexes in this series (19–21) were more potent than
their single fused-ring analogs (13–15).
Next, the in vitro anti-HIV potencies of the SH compounds
towards the CXCR4-using (X4) HIV-1 strain NL4-3 were evalu-
ated in a Tat-inducible, luciferase-based HIV-1 infection assay
with the TZM-bl cell line. As seen from Table 1, the strongest
inhibitory activity (IC50: ca. 0.20 μM) was noted for 14 and 20,
which are Fe3+ complexes with one or two fused rings, respecti-
vely. Zinc complex 21 in the two fused-ring series had equal
potency to 14, within experimental error. Cytotoxicity was also
determined and the values are given in Table 1. The only signifi-
cant toxicity issues were with the more polar metal-free poly-
amines 6 and 12 and the Mn2+ complex bearing a methyl group
in the para position of the pyridine ring, 5. Overall, the anti-
HIV-1 potencies of the SH compounds generally increased with
the degree of hydrophobicity imparted by the number of satu-
rated six-membered rings fused to the pyridine ring in the
complex. In the most hydrophobic series, complexation with Cu,
Zn or Fe (in 19–21) generally improved the antiviral activity of the
complex as compared to Mn (in 17), or the metal-free ligand (18).
Other azamacrocyclic complexes of Zn2+ and Cu2+ have been
reported to exhibit potent anti-HIV activity by binding CXCR4.41
Scheme 3 Syntheses of tetrahydroquinoline and octahydroacridine containing macrocyclic metal complexes and metal-free ligands (12 and 18).
Reagents and conditions: (a) MnCl2, (CH2NHCH2CH2NH2)2, heat. (b) (1) NaBH4, EtOH, 50 °C; (2) LiCl, MeOH. (c) (1) HCl, H2O, rt, 30 min; (2) NaOH,
MeOH. (d) M, EtOH.
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The bicyclam AMD3100 was included in these experiments
as a control, and gave IC50 values of 26 ± 3 nM for CXCL12
binding inhibition and 0.22 ± 0.02 nM for anti-HIV activity,
thus showing approximately 100-fold greater potency in the
anti-HIV assay than in the CXCL12 binding assay. This may be
attributed largely to the experimental differences between
these two assays using different cell types. Interestingly, the
potencies of the SH compounds are more similar in these two
assays and in some cases the CXCL12 binding inhibition
potencies are more than 10-fold higher than the anti-HIV
potencies, particularly for the more hydrophobic Mn com-
plexes 11 and 17. This difference between relative potencies in
the two assays suggests that the SH compounds may bind
differently to the CXCR4 binding site, relative to AMD3100.
The binding pocket of CXCR4 is relatively open and consists of
two subpockets of different sizes.42 Several anionic amino acid
side chains line the pockets, forming salt bridges with ligands,
including CXCL12 and small molecules. It has been estab-
lished that small molecules, including bicyclams, mono-
cyclams, and noncyclams, have multiple modes of binding to
the chemokine binding pocket.7,43 Finally, the submicromolar
potencies observed for Zn complexes 15 and 21 and the more
modest potencies of the metal-free ligands (6, 12, and 18)
show that the CXCR4 binding and anti-HIV activities of these
compounds do not depend on redox activity of the metal
center and therefore are not related to SOD activity.
Conclusions
Three series of pyridine-containing pentaazacylopentadecanes
were synthesized by Mn2+-templated Schiff-base cyclizations of
triethylenetriamine with various dicarbonyl compounds in
which the pyridine ring was fused to zero, one, or two satu-
rated six-membered rings. By evaluating these macrocyclic
polyamines and their complexes with Mn2+, Cu2+, Fe3+, and
Zn2+, we have discovered novel CXCR4-binding compounds
with anti-HIV activity. The Mn2+ complex of a new
pentaazacyclopentadecane with one fused carbocyclic ring (11)
has the greatest potency as an inhibitor of the chemokine
receptor CXCR4, as evidenced by inhibiting binding of
CXCL12 to PBMCs (IC50: 0.014 µM). Consequently, 11 inhibits
replication of the CXCR4-using (X4) HIV-1 strain NL4-3 in the
TZM-bl cell line with an IC50 value of 0.52 µM and has low
cytotoxicity (CC50: >100 µM). In addition, 18 other compounds
were evaluated for their interaction with CXCR4 and their
interference with natural ligand binding and HIV entry and
infection. Of these, the metal complexes of the most hydro-
phobic series with two fused carbocyclic rings exhibited the
greatest potency. The Zn2+ complex (21) was among the most
potent, showing that redox activity of the metal center is not
associated with CXCR4 inhibitory activity. The molecular
mode of binding between these compounds and CXCR4 has
not yet been elucidated, but many CXCR4 inhibitors contain
one or more pyridine rings and highly basic nitrogen atoms
that are protonated at physiologic pH.3,7,37,38 The pyridine
rings and the 2–3 positive charges of these new compounds
suggest that they may bind in a similar manner.
Fig. 3 Solid state structure of the D,L diastereomer of MnCl2 complex
17. Color scheme: C grey, N blue, Cl green.
Table 1 Inhibitory effects of the compounds in CXCL12 chemokine
binding and HIV-1 NL4-3 (X4) replication assays, as well as cellular
toxicities
Compound
CXCL12 binding Anti-HIV-1 activity Cytotoxicity
IC50
a (µM) IC50
b (µM) CC50
c (µM)
1 3.1 ± 0.7 17.2 ± 2.9 >100
3 2.0 ± 0.4 17.0 ± 3.4 >100
5 13.5 ± 5.4 3.0 ± 0.4 21.5
6 55.7 ± 10.3 66.0 ± 23.9 40.1
7 1.9 ± 0.2 2.8 ± 0.8 >100
8 2.5 ± 0.4 18.6 ± 2.4 >100
9 7.6 ± 0.5 67.7 ± 10.8 >100
10 0.107 ± 0.006 1.1 ± 0.2 >100
11 0.014 ± 0.002 0.52 ± 0.05 >100
12 0.177 ± 0.005 0.86 ± 0.28 30.9
13 0.21 ± 0.03 1.8 ± 0.4 >100
14 1.1 ± 0.2 0.25 ± 0.04 >100
15 0.13 ± 0.02 1.1 ± 0.1 >100
16 2.5 ± 0.3 1.9 ± 0.4 99.1
17 0.05 ± 0.01 1.6 ± 0.2 >100
18 0.32 ± 0.03 1.4 ± 0.2 >100
19 0.08 ± 0.02 0.40 ± 0.04 >100
20 0.25 ± 0.08 0.20 ± 0.03 >100
21 0.051 ± 0.005 0.27 ± 0.05 >100
a IC50: 50% inhibitory concentration of the compounds to inhibit
CXCL12-CXCR4 binding on PBMCs after 15 min of drug treatment.
b IC50: 50% inhibitory concentration of the compounds to inhibit
HIV-1 NL4-3 replication in TZM-bl cells after 48 h of drug treatment.
c CC50: 50% cytotoxic concentration of the compounds in TZM-bl cells
after 48 h of drug treatment.
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CXCR4 is well established as a target of great importance
for therapeutic compounds. Some of the experimental SH
compounds, as described above, effectively disrupt the
CXCL12-CXCR4 axis and also prevent the entry of HIV into
cells expressing CXCR4. Taken together, results of the binding
and anti-HIV assays performed in this article appear very
promising. In the future, in vivo experiments will be needed to
further validate the efficacy of these experimental SH com-
pounds, and site directed mutagenesis together with mole-
cular modeling and docking studies might be used to
determine the manner in which these compounds interact
with the ligand-binding pocket of CXCR4.
Experimental section
Chemistry
All reactions were performed under an atmosphere of dry
nitrogen. All starting materials, reagents, and solvents were
used as purchased without further purification, unless other-
wise noted. Anhydrous methanol, acetonitrile and THF were
distilled from Mg powder, CaH2 or Na, respectively. Triethyl-
enetetramine hydrate used in Mn-templated condensation
reactions contained 4.7 eq. of H2O by
1H NMR analysis. Water
used in the formation of metal complexes was deionized then
distilled at atmospheric pressure. Solutions of 2 M HCl in
methanol were prepared by adding 15 mL of con. aq. HCl to
75 mL of methanol. Silica (32–63 µm), from Sorbent Techno-
logies was used for column chromatography. Samples for
microanalysis were dried under vacuum (0.1 mm) at 78 °C for
48 hours, unless otherwise mentioned. Elemental analysis was
performed by NuMega Resonance Laboratories. Melting points
were measured in open glass capillary tubes on a Thomas–
Hoover apparatus and are uncorrected. Infrared (IR) spectra
were recorded on a Nicolet Protégé 460 spectrometer. 1H and
13C NMR spectra were taken on Varian Unity Plus NMR instru-
ments at the indicated operating frequencies. Mass spectro-
metry (MS) was performed with a Waters ZQ electrospray
ionization (ESI) quadrupole micromass spectrometer (capillary
3.0 kV). X-ray crystallographic data were obtained on a Bruker
APEX CCD diffractometer equipped at low temperature (100 ±
1 K) using Mo Kα radiation (λ = 0.71073 Å) and a detector-to-
crystal distance of 4.94 cm. Data collection for complexes was
optimized utilizing the APEX2 software with a 0.5° rotation
about ω between frames, and an exposure time of 10 s per
frame. Data integration, correction for Lorentz and polariz-
ation effects, and final cell refinement were performed using
SAINTPLUS, and corrected for absorption using SADABS. The
structures were solved using direct methods followed by suc-
cessive least squares refinement on F2 using the SHELXTL.44
All non-hydrogen atoms were refined anisotropically and
hydrogen atoms placed in calculated positions.
Synthesis of 3,6,9,12,18-pentaazabicyclo[12.3.1]octadeca-
1(18),2,12,14,16-pentaene dichloromanganese(II) (3). A mixture
of 0.51 g (3.7 mmol) of pyridine-2,6-dicarboxaldehyde,38 0.74 g
(3.7 mmol) of MnCl2·4H2O, 15 mL of water and 1 mL of metha-
nol was stirred at 50 °C for 1.5 h. The resulting pale yellow
solution was cooled to room temperature and stirred as a solu-
tion of 0.85 g (3.7 mmol) of triethylenetetraamine hydrate in
1 mL of water was added dropwise over 10 min. The reaction
mixture was boiled under reflux for 3 h then stood at room
temperature overnight. The resulting brown mixture was fil-
tered the filtrate concentrated to dryness by rotary evaporation
(bath temp. 60 °C). The residue was dried (0.1 mm) overnight
to give a reddish brown solid. A 1.21 g sample of the crude
product was purified by column chromatography, eluting with
2.5 : 97.5 to 15 : 85 (v/v) methanol/dichloromethane, yielding
0.34 g (29%) of pure 3. MS (ESI+) m/z 335 (M − Cl, 100%); 299
(M − H − 2Cl, 50%). IR (neat, cm−1) 3285 (w), 3232 (w), 3058
(w), 2915 (w), 2849 (w), 1653 (w), 1584 (w), 1455 (w), 1428 (w),
1327 (w), 1273 (w), 1183 (w), 1142 (w), 1106 (m), 1042 (s), 1013
(m), 973 (m), 876 (m), 858 (s), 826 (s), 807 (m), 796 (s), 753 (w),
660 (m), 637 (m). Anal. Calcd for C13H19Cl2MnN5: C, 42.07; H,
5.16; N, 18.87. Found: C, 42.46; H, 5.31; N, 18.52.
Synthesis of 3,6,9,12,18-pentaazabicyclo[12.3.1]octadeca-
1(18),14,16-triene dichloromanganese(II) (1).21,26–28 A mixture
of 4.44 g (32.9 mmol) of pyridine-2,6-dicarboxaldehyde,38
6.57 g (33.2 mmol) of MnCl2·4H2O, and 150 mL of water was
stirred at 50 °C for 1 h. The resulting pale yellow solution was
cooled to room temperature and stirred as a solution of 7.50 g
(32.6 mmol) of triethylenetetraamine hydrate in 15 mL of
water was added dropwise over a period of 50 min. The reac-
tion mixture was boiled under reflux for 3 h then stood at
room temperature overnight. The resulting brown mixture was
filtered and the filtrate was concentrated to dryness by rotary
evaporation (bath temp. 60 °C). The residue was dried
(0.1 mm) overnight to yield the Schiff base-manganese
complex, as a reddish brown solid. A solution of this inter-
mediate in 300 mL of ethanol was stirred at room temperature
as 10 g (0.27 mol) of NaBH4 was added in two portions. The
resulting suspension was stirred at room temperature for 2 h,
then at 50 °C for 5 h. The solvent was removed by rotary evap-
oration, the residue was stirred for 10 h with 400 mL of a 0.5
M solution of LiCl in methanol, and the solvent was again
removed by rotary evaporation. Water (180 mL) and 28 g
(0.47 mol) of NaCl were added. The mixture was stirred until
all solid dissolved, then extracted with dichloromethane (4 ×
50 mL). The combined extracts were dried (Na2SO4), filtered,
and concentrated to dryness by rotary evaporation. Drying
(0.1 mm) gave 7.75 g (63%) of a light brown solid. The crude
product was purified by column chromatography, eluting with
9 : 1 (v/v) dichloromethane/methanol, yielding 6.09 g (49%) of
1 as a white solid, mp 255–265 °C (dec). MS (ESI+) m/z 339
(M − Cl, 65%), 152 (M − 2Cl(2+), 100%). IR (neat, cm−1) 3453
(w), 3276 (w), 3209 (w), 2897 (w), 2851 (w), 1602 (w), 1577 (w),
1457 (m), 1336 (w), 1297 (w), 1203 (w), 1118 (m), 1012 (m), 934
(w), 885 (m), 847 (m), 801 (s). Anal. Calcd for C13H23Cl2MnN5:
C, 41.61; H, 6.18; N, 18.67. Found: C, 41.46; H, 6.43; N, 18.87.
Synthesis of 3,6,9,12,18-pentaazabicyclo[12.3.1]octadeca-
1(18),14,16-triene (6). A solution of 1.21 g (3.23 mmol) of 1 in
40 mL of 2 M aq. HCl was stirred for 0.5 h at room temperature
then concentrated to dryness by rotary evaporation (bath
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temp. 40 °C, 50–100 mm). The residue was stirred with
16.5 mL of 5 M aq. NaOH for 5 h, then 5 g of NaCl was added
with stirring. The mixture was filtered and the filtrate was
extracted with chloroform (1 × 20 mL, 2 × 10 mL). The com-
bined extracts were dried (Na2SO4), filtered, and concentrated
to dryness by rotary evaporation. Drying (0.1 mm) gave 0.80 g
(99%) of 6 as a white solid, mp 62–65 °C. A sample for micro-
analysis was obtained by stirring 0.49 g of the solid in 20 mL
of ether, filtering, rotary evaporating the filtrate, and drying
the resulting residue (0.1 mm), yielding 0.26 g (32%) of pure 6
as a white solid, mp 64–65 °C. 1H NMR (CDCl3, 400 MHz)
δ 7.54 (t, J = 7.6 Hz, 1 H, H16), 7.03 (d, J = 7.4 Hz, 2 H, H15,17),
3.90 (s, 4 H, H2,13), 2.85 (m, 4 H, H4,11), 2.78 (m, 4 H, H5,10),
2.73 (s, 4 H, H7,8). 13C NMR (CDCl3, 100 MHz) δ 159.0, 136.8,
120.8, 54.1, 48.9, 48.8, 48.7. MS (ESI+) m/z 272 (M + Na, 20%),
250 (M + H, 100%). IR (neat, cm−1) 3312 (w), 3273 (w), 3049
(w), 2870 (m), 2791 (m), 1671 (w), 1586 (w), 1572 (m), 1448 (s),
1129 (m), 1120 (m), 1070 (m), 1045 (m), 875 (m), 816 (m), 759
(m), 709 (s). Anal. Calcd for C13H23N5: C, 62.62; H, 9.30; N,
28.09. Found: C, 62.26; H, 9.03; N, 27.70.
Synthesis of 3,6,9,12,18-pentaazabicyclo[12.3.1]octadeca-
1(18),14,16-triene trichloroiron(III) (7). To a solution of 30 mg
(0.12 mmol) of 6 in 2 mL of ethanol, a solution of 20 mg
(0.12 mmol) of FeCl3 in 3 mL of ethanol was added dropwise.
The resulting mixture was swirled for 0.5 h at room tempera-
ture. The solvent removed by rotary evaporation. The residue
was washed with 5 mL of ether then stirred with 60 mL of
dichloromethane. Filtration, evaporation of the filtrate and
drying the resulting residue (0.1 mm) gave 44 mg (88%) of 7 as
a green solid. MS (ESI+) m/z 375 (M − Cl, 18%), 339 (M − H −
2Cl, 100%), 303 (M − 2H − 3Cl, 30%). IR (neat, cm−1) 3554 (w),
3379 (w), 3218 (w), 3148 (w), 2920 (w), 2870 (w), 1610 (m), 1578
(w), 1477 (m), 1451 (m), 1296 (w), 1277 (w), 1211 (w), 1160 (m),
1106 (m), 1090 (m), 1055 (m), 1030 (m), 1017 (m), 970 (s), 929
(s), 884 (m), 846 (m), 793 (m), 568 (m), 530 (m). Anal. Calcd for
C13H23Cl3 FeN5·2H2O: C, 34.88; H, 6.08; N, 15.65. Found: C,
35.18; H, 5.71; N, 15.93.
Synthesis of 3,6,9,12,18-pentaazabicyclo[12.3.1]octadeca-
1(18),14,16-triene dichlorozinc(II) (8). To a solution of 84 mg
(0.34 mmol) of 6 in 0.5 mL of ethanol, a solution of 46 mg
(0.33 mmol) of ZnCl2 in 2 mL of ethanol was added dropwise.
A white precipitate dissolved upon swirling. The solvent was
removed by rotary evaporation to give a colorless oil. Diethyl
ether (5 mL) was added and the resulting white solid collected
by filtration, rinsed with 2 mL of ether and dried (0.1 mm). A
solution of this solid in dichloromethane was washed with
saturated aq. NaCl, dried (Na2SO4), filtered, and concentrated
to dryness by rotary evaporation. The resulting residue was
dried (0.1 mm), giving 75 mg (57%) of 8 as a white solid.
1H NMR (CDCl3, 500 MHz) δ 7.79 (t, J = 8 Hz, 1 H, H16), 7.21
(d, J = 8 Hz, 2 H, H15,17), 4.47 (br, 2 H, H2,13), 3.81 (br, 4 H,
NH), 3.61 (br, 2 H, H2′,13′), 3.22 (br, 6 H, H5,7,8,10), 2.69 (s,
6 H, H5′,7′,8′,10′). 13C NMR (CDCl3, 125 MHz) δ 154.5, 140.0,
121.6, 49.8, 47.1, 45.8, 44.1. MS (ESI+) m/z 348 (M − Cl, 90%),
312 (M − H − 2Cl, 100%). IR (neat, cm−1) 3474 (w), 3303 (w),
3240 (w), 3217 (w), 3175 (w), 3139 (w), 2912 (w), 2867 (w), 1626
(w), 1604 (m), 1581 (w), 1465 (m), 1439 (m), 1336 (w), 1119 (m),
1083 (m), 1020 (s), 959 (s), 941 (s), 796 (s). Anal. Calcd for
C13H23Cl2N5Zn·H2O: C, 38.68; H, 6.24; N, 17.35. Found: C,
38.40; H, 6.42; N, 17.13.
Synthesis of 3,6,9,12,18-pentaazabicyclo[12.3.1]octadeca-
1(18),14,16-triene dichlorocopper(II) (9). To a solution of
89 mg (0.36 mmol) of 6 in 1.5 mL of ethanol, a solution of
48 mg (0.35 mmol) of copper(II) chloride in 1 mL of ethanol
was added dropwise. The resulting mixture was swirled for
0.5 h at room temperature. The solvent was removed by rotary
evaporation and residue was dried (0.1 mm) to give a blue
solid. A solution of this solid in 9 mL of dichloromethane was
filtered and the filtrate was evaporated to obtain 116 mg (86%)
of 9 as a blue solid. A sample for microanalysis was prepared
by slow diffusion of ether into the solution of the complex in
1 mL of ethanol. The resulting precipitate was filtered and
dried (0.1 mm) to give 93 mg (69%) of pure 9 as a blue solid.
MS (ESI+) m/z 347 (M − Cl, 15%), 311 (M − H − 2Cl, 100%).
IR (neat, cm−1) 3324 (w), 3217 (w), 3142 (w), 3080 (w), 2881 (w),
1608 (w), 1584 (w), 1477 (s), 1452 (w), 1420 (m), 1357 (w), 1339
(w), 1076 (s), 1041 (s), 1012 (w), 983 (m), 942 (s), 915 (m), 844
(w), 831 (w), 809 (w), 778 (w), 675 (w). Anal. Calcd for
C13H23Cl2 CuN5·0.5H2O: C, 39.75; H, 6.16; N, 17.83. Found: C,
39.31; H, 6.10; N, 17.85.
Biological evaluation
CXCL12AF647 binding assay.45 Peripheral blood mono-
nuclear cells (PBMCs) were isolated out of buffy coats from
healthy donors, derived from the blood transfusion center
(Red Cross, Belgium) by density centrifugation. The anon-
ymous donors signed informed consent agreements allowing
their blood to be used for scientific research. The cells were
cultured in RPMI-1640 medium supplemented with 10% FCS
and 1% L-glutamine. PBMCs were stimulated with 2 μg ml−1
phytohemagglutinin (PHA) for 3 days at 37 °C. The cells were
washed once with assay buffer (Hanks’ balanced salt solution
with 20 mM HEPES buffer and 0.2% bovine serum albumin,
pH 7.4) and then incubated for 15 min at room temperature
with the SH compounds diluted in assay buffer. Subsequently,
fluorescent CXCL12AF647 (25 ng ml−1) was added to the com-
pound-incubated cells. The cells were incubated for 30 min at
room temperature. Thereafter, the cells were washed twice in
assay buffer, fixed in 1% paraformaldehyde in PBS, and ana-
lyzed on a FACSArray flow cytometer equipped with a 635 nm
red diode laser (Becton Dickinson, San Jose, CA, USA). The per-
centages of inhibition of CXCL12AF647 binding were calculated
according to the formula: [1 − ((MFI − MFINC)/(MFIPC −
MFINC))] × 100, where MFI is the mean fluorescence intensity
of the cells incubated with CXCL12AF647 in the presence of the
inhibitor, MFINC is the mean fluorescence intensity measured
in the negative control (i.e., autofluorescence of unlabeled
cells), and MFIPC is the mean fluorescence intensity of the
positive control (i.e., cells exposed to CXCL12AF647 alone).
HIV infection assay.46,47 TZM-bl cells were seeded in trans-
parent 96-well plates at 104 cells per well in DMEM (Dulbecco’s
Modified Eagle Medium; Life Technologies, Waltham, MA,
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USA) with 10% Fetal Bovine Serum (FBS) and 10 mM HEPES.
Subsequently, compounds were added and the cell/compound
mixture was incubated at 37 °C. After 30 min, virus was added
at 100 pg p-24 per well. HIV-1 NL4-3 (CXCR4-using, X4) was
obtained through the AIDS Research and Reference Reagent
Program (Division of AIDS, NIAID, NIH). After 48 h of incu-
bation, the assay plates were analyzed. For the analysis, steady-
lite plus substrate solution (PerkinElmer, Waltham, MA, USA)
was added to the assay plates. The luminescent signal of the
lysed cell suspension was analyzed in white 96-well plates on a
SpectraMax L luminescence microplate reader (Molecular
Devices, Sunnyvale, CA, USA) after a 10 min incubation period
in the dark. Luciferase activity induced by HIV-1 Tat protein
expression was measured as an assessment of the amount
of HIV replication. The 50% cytotoxic concentration (CC50) of
compounds was determined from the reduction of viability of
uninfected TZM-bl cells exposed to the compounds, as
measured by the MTS/phenazine ethosulfate (PES) method
described above.
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